KC1086 not checked
Beijing Konruns Pharmaceutical Co., Ltd.
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Dosage: based on the doses selected in Part 1 (high dose and low dose); Route: Oral; Frequency: Once daily (QD) under fasting conditions (at least 2 hours before and 1 hour after dosing), 28 days as a cycle.”In the company’s words, NCT07937605 on ClinicalTrials.gov
- Tested for
- HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer, Advanced Solid Tumors Cancer
- Main trialPhase 2
- “The purpose of this study is to evaluate the safety, efficacy, and pharmacokinetic characteristics of KC1086 in combination with fulvestrant in adults with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) locally advanced or metastatic breast cancer.”In the company’s words, NCT07937605 on ClinicalTrials.gov
Other drugs for HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer
- D-0502InventisBio Co., Ltd · Phase 3
- ElacestrantStemline Therapeutics, Inc. · Phase 3
- YL202MediLink Therapeutics (Suzhou) Co., Ltd. · Phase 3
- SPH4336Shanghai Pharmaceuticals Holding Co., Ltd · Phase 2/3
- PembrolizumabMerck & Co. · Phase 3
- NiraparibGSK · Phase 3
Coming up2
- Aug 2028Phase 1 trial completes · ClinicalTrials.gov
- Nov 2029Phase 2 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 16 NovNew trial: none to Phase 2 · ClinicalTrials.gov NCT07937605
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Not yet recruiting | Nov 2029 | KC1086 in Combination With Fulvestrant for HR-Positive, HER2-Negative Advanced Breast Cancer | |
| Phase 1Not yet recruiting | Aug 2028 | A Study of KC1086 in Patients With Advanced Solid Tumors |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026